Last update 20 Mar 2025

Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
AntiEGFR/IL13R2 CAR T cell therapy, AntiEGFR/IL13Ra2 CAR T cell therapy, AntiEGFR/IL13Ralfa2 CAR T cell therapy
Target
EGFR x IL-13Rα2
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors), Gene transference
+ [1]
Therapeutic Areas
NeoplasmsNervous System DiseasesOther Diseases
Active Indication
EGFR mutation GlioblastomaRecurrent GlioblastomaGlioblastoma
Inactive Indication
Glioblastoma Multiforme
Originator Organization
University of PennsylvaniaUniversity of PennsylvaniaTmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.Startup
Active Organization
Gilead Sciences, Inc.Gilead Sciences, Inc.University of PennsylvaniaUniversity of PennsylvaniaTmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
NCT05168423
/ RecruitingPhase 1IIT
Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
NCT03726515
/ CompletedPhase 1IIT
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
100 Clinical Results associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Translational Medicine associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Patents (Medical) associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Deals associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR mutation GlioblastomaPhase 1
United States
University of PennsylvaniaUniversity of Pennsylvania
24 Feb 2023
EGFR mutation GlioblastomaPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
24 Feb 2023
Recurrent GlioblastomaPhase 1
United States
University of PennsylvaniaUniversity of Pennsylvania
24 Feb 2023
Recurrent GlioblastomaPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
24 Feb 2023
GlioblastomaPreclinical
United States
Tmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.Startup
-
Glioblastoma MultiformeDiscovery
United States
University of PennsylvaniaUniversity of Pennsylvania
11 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free